View Financial HealthParkerVision 배당 및 자사주 매입배당 기준 점검 0/6ParkerVision 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-15.3%자사주 매입 수익률총 주주 수익률-15.3%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Nov 22ParkerVision, Inc. announced that it expects to receive $3.461132 million in fundingParkerVision, Inc. entered into subscription agreements with accredited investors on November 21, 2025. Pursuant to the agreement the Investors agreed to purchase an aggregate of 16,481,579 shares of the Company’s common stock, par value $0.01 per share, at a purchase price of $0.21 per share, for an aggregate purchase price of approximately $3,461,132. The closing of the transaction is expected to occur on November 24, 2025.공시 • Aug 19ParkerVision, Inc., Annual General Meeting, Sep 30, 2025ParkerVision, Inc., Annual General Meeting, Sep 30, 2025.공시 • Apr 22Parkervision, Inc. Announces Resignation of Sanford Litvack from Board of Directors, and from Audit and Compensation Committees, Effective April 15, 2025ParkerVision, Inc. announced thatoOn April 15, 2025, Mr. Sanford Litvack resigned from Board of Directors, and from the Audit and Compensation Committees on which he served.공시 • Sep 07ParkerVision, Inc. Announces Appellate Court Overturns District Court in A Precedential Ruling, Sends Parkervision V Qualcomm Back to Florida for TrialParkerVision, Inc. announced that the United States Court of Appeals for the Federal Circuit (CAFC) has issued a favorable ruling in ParkerVision v. Qualcomm (Case No. 2022-1755). The CAFC upheld ParkerVision's position on each of the appealed issues and has sent the case back to the Middle District of Florida (District Court) for trial. The CAFC opinion: Reversed the District Court's Daubert ruling, which had deemed ParkerVision's expert report inadmissible and likewise vacated the District Court's grant of summary judgement of non-infringement of the transmitter claims which was based on the exclusion of ParkerVision's infringement experts. The District Court had dismissed the evidence supporting ParkerVision's patent infringement claims because the expert did not create his own simulations of Qualcomm's accused radio frequency chips. However, the CAFC found that the District Court abused its discretion in excluding the testimony of ParkerVision's validity expert, stating "the district court should have left it to jurors to evaluate the correctness of facts underlying an expert's testimony". This reversal reinstates ParkerVision's expert report, allowing the Company to present its infringement claims against Qualcomm to a jury. Vacated the District Court's summary judgement ruling, which had barred ParkerVision from asserting its radio frequency receiver patents in this case. The lower court had based its decision on the argument that these patents are essentially the same as other ParkerVision receiver patents previously asserted against Qualcomm in 2011. The CAFC found that the District Court erred in its determination that the asserted receiver claims did not have a scope that is materially different from the claims at issue in the 2011 case and remanded for further consideration. Reversed the District Court's application of collateral estoppel, which prevented ParkerVision from defending the validity of its ‘940 patent using arguments it previously presented to the Patent Trial and Appeal Board (PTAB) and the CAFC. These arguments had been successful in a prior inter partes review (IPR) proceeding initiated by Qualcomm in 2015 which delayed the patent infringement case until 2019. The CAFC has remanded the case to the U.S. District Court for the Middle District of Florida, ordering the reopening of the original case (Case No. 6:14-cv-00687). ParkerVision initiated this case against Qualcomm in the Federal District Court in Orlando, Florida, in May 2014 while awaiting a final decision on a separate 2011 patent infringement case involving different receiver patents. The case experienced several delays due to Qualcomm's IPR challenges to patent validity and court closures caused by the pandemic. By May 2021, all final pre-trial motions had been filed. With courts reopening in 2022, the District Court held a pre-trial motion hearing in January 2022, signaling preparation for a near-term jury trial. However, in March 2022, the District Court issued orders in Qualcomm's favor on all motions, effectively barring ParkerVision from presenting the case to a jury. The court subsequently closed the case file. ParkerVision appealed three of the District Court's rulings to the CAFC, and by the end of 2022, both parties had submitted their appellate briefs and replies. In November 2023, the CAFC permitted oral arguments to support these briefs. However, in July 2024, the CAFC found that it lacked proper jurisdiction over the case because the District Court had not issued a final order on Qualcomm's counterclaims for invalidity. Subsequently, the parties filed a joint motion with the District Court. On August 1, 2024, the District Court issued an order dismissing Qualcomm's invalidity counterclaims, without prejudice, clearing the way for the CAFC to proceed with its ruling on the appeal.공시 • Sep 02ParkerVision, Inc., Annual General Meeting, Oct 28, 2024ParkerVision, Inc., Annual General Meeting, Oct 28, 2024.공시 • Aug 03ParkerVision, Inc., Annual General Meeting, Sep 15, 2023ParkerVision, Inc., Annual General Meeting, Sep 15, 2023, at 11:00 Eastern Standard Time. Agenda: To elect two Class I directors until the term of Class I directors ends in 2026 and to elect one Class II director until the term of Class II directors ends in 2024; to approve, on an advisory basis, the company’s named executive officer compensation ("Say on Pay"); to ratify the selection of MSL, P.A. as the company’s independent registered public accounting firm for the year ending December 31, 2023; and to discuss other matters.공시 • Jun 27ParkerVision, Inc. Appoints Lewis (Lew) H. Titterton as Class II DirectorParkerVision, Inc. announced that it has appointed Mr. Lewis (Lew) H. Titterton, Jr. as a Class II director to fill a vacancy on the company's board of directors. Mr. Titterton previously served on the ParkerVision board from September 2018 until April 2019 when he resigned due to family medical issues. Mr. Titterton has served on the board of directors of Anixa Biosciences since July 2017, including as lead independent director since July 2018 and chairman of the board from 2012 to 2016. His background is in high technology with an emphasis on health care and he was the chairman of the board of directors of NYMED, Inc. from 1989 until October 2018. Mr. Titterton founded MedE America, Inc. in 1986 and was the chief executive officer of Management and Planning Services, Inc. from 1978 to 1986. He holds an MBA from the State University of New York at Albany, and a B.A. degree from Cornell University.공시 • Jan 24ParkerVision, Inc. announced that it has received $0.835 million in fundingOn January 23, 2023, ParkerVision, Inc. closed the transaction. The transaction included participation from five investors.공시 • Jan 10ParkerVision, Inc. announced that it has received $1 million in fundingOn January 9, 2023, ParkerVision, Inc. closed the transaction. The transaction included participation from a single investor공시 • Dec 16ParkerVision, Inc. announced that it has received $0.2 million in fundingOn December 14, 2022, ParkerVision, Inc. closed the transaction. The transaction included participation from a single investor.공시 • Nov 01ParkerVision, Inc. Appoints Sanford M. Litvack as Board of DirectorParkerVision, Inc. announced that it has named Sanford (Sandy) Litvack to its Board of Directors, expanding the Board to five members, four of whom are independent. Mr. Litvack is a partner with Chaffetz Lindsey LLP and has a broad corporate litigation background, handling a wide array of complex matters, including patent and other intellectual property issues. Litvack served as Assistant Attorney General in charge of the Antitrust Division of the Department of Justice and was selected by President George W. Bush to serve as a member of the Antitrust Modernization Commission. In addition to his courtroom experience, Mr. Litvack spent a decade at the Walt Disney Company holding various roles from general counsel to chief of corporate operations and vice chairman of the board of directors. He is also a former director of Hewlett Packard. Mr. Litvack currently serves on the board of directors for L Catterton Asia Acquisition Corp., a special purpose acquisition company.공시 • Aug 18ParkerVision, Inc. announced that it has received $1.6675 million in fundingOn August 17, 2022, ParkerVision, Inc. closed the transaction. The transaction included participation from 13 investors.공시 • Aug 03ParkerVision, Inc., Annual General Meeting, Sep 16, 2022ParkerVision, Inc., Annual General Meeting, Sep 16, 2022, at 10:00 US Eastern Standard Time. Agenda: To elect two Class III members of the Board to hold office until the third ensuing annual meeting and until his respective successor is duly elected and qualified; to approve an amendment to the amended and restated articles of incorporation of the company, as amended, to increase the number of authorized shares of common stock from 150,000,000 shares to 175,000,000 shares; to ratify the appointment of MSL, P.A. as the company's independent registered public accounting firm for the year ending December 31, 2022; and to transact such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof.공시 • Jul 02ParkerVision, Inc. announced that it has received $0.35 million in funding from Forge Trust Company, and other investorsParkerVision, Inc. announced that it has entered into a purchase agreement for a private placement of 8% unsecured convertible promissory notes for gross proceeds of $350,000on June 30, 2022. The transaction included participation from Forge Trust Company for $200,000, The Trustee of the Judson Dean LaCapra Revocable Trust for $25,000, individual investors John F. Levy for $100,000, Wilhem Boulay for $25,000. The notes bear interest at a fixed rate of 8% per annum and is payable quarterly either in cash, shares of common stock, or a combination thereof at the company's option, subject to certain equity conditions, on the 15th of April, July, October, and January of each year during the five year term of the notes, expiring June 30, 2027. The notes are convertible at any time and from time to time by the Holders into shares of common stock at a fixed conversion price of $0.13 per share. The company issued securities in reliance on the exemption afforded by Section 4(a)(2) of the Securities Act of 1933 and Rule 506(b) of Regulation D promulgated thereunder.공시 • Jun 03ParkerVision, Inc. announced that it has received $0.76 million in funding from Alpine Partners (Bvi), L.P., Thomas Staz Revocable TrustParkerVision, Inc. announced that it has entered into a note and warrant purchase agreement for a private placement of 8% unsecured convertible promissory notes for gross proceeds of $760,000 on June 2, 2022. The transaction included participation from Thomas Staz Revocable Trust for $65,000, Alpine Partners (BVI) LP for $500,000, individual investors, Harold Wrobel for $130,000 and Ronald T. Bevans, Jr. for $65,000. The notes bear interest at a fixed rate of 8% per annum and is payable quarterly either in cash, shares of common stock, or a combination thereof at the company's option, subject to certain equity conditions, on the 15th of April, July, October, and January of each year during the five year term of the notes, expiring June 2, 2027. The notes are convertible at any time and from time to time by the Holders into shares of common stock at a fixed conversion price of $0.13 per share. The company issued securities in reliance on the exemption afforded by Section 4(a)(2) of the Securities Act of 1933 and Rule 506(b) of Regulation D promulgated thereunder.공시 • Mar 29ParkerVision, Inc. Announces that Orlando Court Grants Qualcomm Motion for Summary JudgmentParkerVision, Inc. announced that on March 22, 2022, the U.S. District Court in the Middle District of Florida ruled in Qualcomm’s favor on a motion styled as Qualcomm’s motion for “non-infringement and invalidity” (Dkt. 494) in ParkerVision v. Qualcomm (Case no. 6:14-cv-00687). The court’s order, which is sealed “for attorney’s eyes only,” determines that Qualcomm does not infringe the asserted claims of the remaining three patents-in-suit. It makes no findings as to the invalidity of any of the asserted claims of the remaining three patents-in-suit. This is a final order, meaning the next step is an appeal. ParkerVision intends to appeal this ruling, along with this same court’s March 9, 2022 ruling excluding opinions of the Company’s experts regarding infringement and validity issues.공시 • Mar 31ParkerVision, Inc. announced that it has received $3.6 million in fundingParkerVision, Inc. (OTCPK:PRKR) announced a private placement of units at an issue price of $1.29 per unit for gross priceeds of $3,600,000 on March 29, 2021. Each unit consists of one common share and half warrant. Each warrant is exercisable into shares at an exercise p[rice of $1.75 per share for a period of five years.공시 • Oct 05Parkervision Inc. to Report Q4, 2009 Results on 03/15/2010Parkervision Inc. announced that they will report Q4, 2009 results on 03/15/2010공시 • Aug 22+ 1 more updateParkerVision, Inc. announced that it has received $0.352701 million in funding from Gem Investment Advisors, LLCOn August 21, 2020, ParkerVision, Inc. closed the transaction. The company received $352,700 pursuant to regulation D.공시 • Aug 07+ 1 more updateParkerVision, Inc. announced that it has received $0.1745 million in fundingOn August 6, 2020, ParkerVision, Inc. (OTCPK:PRKR) closed the transaction. The transaction included participation from 3 investors.공시 • Jul 07ParkerVision, Inc. announced that it has received $0.215201 million in fundingParkerVision, Inc. (OTCPK:PRKR) announced that it has entered into securities purchase agreements to issue 614,859 shares at a price of $0.35 per share for gross proceeds of $215,201 on June 29, 2020. The purchase agreements also provide the investors with a contingent payment right whereby the company will pay each investor an allocated portion of the company’s net proceeds from its patent claims, after taking into account fees and expenses payable to law firms representing the company and amounts payable to the company’s litigation financer. The transaction will include participation from individual investors including Dennis Mehiel for 285,715 shares amounting to $100,000, Aileen Gregoire for 100,000 shares amounting to $35,000, Wenyu Luo for 85,715 amounting to $30,000, John Birdsall & Margaret Mintz for 72,000 amounting to $25,200, Manal Eldumiati for 71,429 amounting to $25,000. The shares will be offered and sold on a private placement basis under Section 4(a)(2) of the Securities Act of 1933 and Rule 506. The company received funding from 7 investors pursuant to Regulation D.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 PRKR 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: PRKR 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장ParkerVision 배당 수익률 vs 시장PRKR의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (PRKR)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Communications)1.7%분석가 예측 (PRKR) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 PRKR 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 PRKR 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 PRKR 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: PRKR 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/22 06:59종가2026/05/22 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스ParkerVision, Inc.는 1명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Jon HickmanLadenburg Thalmann & Company
공시 • Nov 22ParkerVision, Inc. announced that it expects to receive $3.461132 million in fundingParkerVision, Inc. entered into subscription agreements with accredited investors on November 21, 2025. Pursuant to the agreement the Investors agreed to purchase an aggregate of 16,481,579 shares of the Company’s common stock, par value $0.01 per share, at a purchase price of $0.21 per share, for an aggregate purchase price of approximately $3,461,132. The closing of the transaction is expected to occur on November 24, 2025.
공시 • Aug 19ParkerVision, Inc., Annual General Meeting, Sep 30, 2025ParkerVision, Inc., Annual General Meeting, Sep 30, 2025.
공시 • Apr 22Parkervision, Inc. Announces Resignation of Sanford Litvack from Board of Directors, and from Audit and Compensation Committees, Effective April 15, 2025ParkerVision, Inc. announced thatoOn April 15, 2025, Mr. Sanford Litvack resigned from Board of Directors, and from the Audit and Compensation Committees on which he served.
공시 • Sep 07ParkerVision, Inc. Announces Appellate Court Overturns District Court in A Precedential Ruling, Sends Parkervision V Qualcomm Back to Florida for TrialParkerVision, Inc. announced that the United States Court of Appeals for the Federal Circuit (CAFC) has issued a favorable ruling in ParkerVision v. Qualcomm (Case No. 2022-1755). The CAFC upheld ParkerVision's position on each of the appealed issues and has sent the case back to the Middle District of Florida (District Court) for trial. The CAFC opinion: Reversed the District Court's Daubert ruling, which had deemed ParkerVision's expert report inadmissible and likewise vacated the District Court's grant of summary judgement of non-infringement of the transmitter claims which was based on the exclusion of ParkerVision's infringement experts. The District Court had dismissed the evidence supporting ParkerVision's patent infringement claims because the expert did not create his own simulations of Qualcomm's accused radio frequency chips. However, the CAFC found that the District Court abused its discretion in excluding the testimony of ParkerVision's validity expert, stating "the district court should have left it to jurors to evaluate the correctness of facts underlying an expert's testimony". This reversal reinstates ParkerVision's expert report, allowing the Company to present its infringement claims against Qualcomm to a jury. Vacated the District Court's summary judgement ruling, which had barred ParkerVision from asserting its radio frequency receiver patents in this case. The lower court had based its decision on the argument that these patents are essentially the same as other ParkerVision receiver patents previously asserted against Qualcomm in 2011. The CAFC found that the District Court erred in its determination that the asserted receiver claims did not have a scope that is materially different from the claims at issue in the 2011 case and remanded for further consideration. Reversed the District Court's application of collateral estoppel, which prevented ParkerVision from defending the validity of its ‘940 patent using arguments it previously presented to the Patent Trial and Appeal Board (PTAB) and the CAFC. These arguments had been successful in a prior inter partes review (IPR) proceeding initiated by Qualcomm in 2015 which delayed the patent infringement case until 2019. The CAFC has remanded the case to the U.S. District Court for the Middle District of Florida, ordering the reopening of the original case (Case No. 6:14-cv-00687). ParkerVision initiated this case against Qualcomm in the Federal District Court in Orlando, Florida, in May 2014 while awaiting a final decision on a separate 2011 patent infringement case involving different receiver patents. The case experienced several delays due to Qualcomm's IPR challenges to patent validity and court closures caused by the pandemic. By May 2021, all final pre-trial motions had been filed. With courts reopening in 2022, the District Court held a pre-trial motion hearing in January 2022, signaling preparation for a near-term jury trial. However, in March 2022, the District Court issued orders in Qualcomm's favor on all motions, effectively barring ParkerVision from presenting the case to a jury. The court subsequently closed the case file. ParkerVision appealed three of the District Court's rulings to the CAFC, and by the end of 2022, both parties had submitted their appellate briefs and replies. In November 2023, the CAFC permitted oral arguments to support these briefs. However, in July 2024, the CAFC found that it lacked proper jurisdiction over the case because the District Court had not issued a final order on Qualcomm's counterclaims for invalidity. Subsequently, the parties filed a joint motion with the District Court. On August 1, 2024, the District Court issued an order dismissing Qualcomm's invalidity counterclaims, without prejudice, clearing the way for the CAFC to proceed with its ruling on the appeal.
공시 • Sep 02ParkerVision, Inc., Annual General Meeting, Oct 28, 2024ParkerVision, Inc., Annual General Meeting, Oct 28, 2024.
공시 • Aug 03ParkerVision, Inc., Annual General Meeting, Sep 15, 2023ParkerVision, Inc., Annual General Meeting, Sep 15, 2023, at 11:00 Eastern Standard Time. Agenda: To elect two Class I directors until the term of Class I directors ends in 2026 and to elect one Class II director until the term of Class II directors ends in 2024; to approve, on an advisory basis, the company’s named executive officer compensation ("Say on Pay"); to ratify the selection of MSL, P.A. as the company’s independent registered public accounting firm for the year ending December 31, 2023; and to discuss other matters.
공시 • Jun 27ParkerVision, Inc. Appoints Lewis (Lew) H. Titterton as Class II DirectorParkerVision, Inc. announced that it has appointed Mr. Lewis (Lew) H. Titterton, Jr. as a Class II director to fill a vacancy on the company's board of directors. Mr. Titterton previously served on the ParkerVision board from September 2018 until April 2019 when he resigned due to family medical issues. Mr. Titterton has served on the board of directors of Anixa Biosciences since July 2017, including as lead independent director since July 2018 and chairman of the board from 2012 to 2016. His background is in high technology with an emphasis on health care and he was the chairman of the board of directors of NYMED, Inc. from 1989 until October 2018. Mr. Titterton founded MedE America, Inc. in 1986 and was the chief executive officer of Management and Planning Services, Inc. from 1978 to 1986. He holds an MBA from the State University of New York at Albany, and a B.A. degree from Cornell University.
공시 • Jan 24ParkerVision, Inc. announced that it has received $0.835 million in fundingOn January 23, 2023, ParkerVision, Inc. closed the transaction. The transaction included participation from five investors.
공시 • Jan 10ParkerVision, Inc. announced that it has received $1 million in fundingOn January 9, 2023, ParkerVision, Inc. closed the transaction. The transaction included participation from a single investor
공시 • Dec 16ParkerVision, Inc. announced that it has received $0.2 million in fundingOn December 14, 2022, ParkerVision, Inc. closed the transaction. The transaction included participation from a single investor.
공시 • Nov 01ParkerVision, Inc. Appoints Sanford M. Litvack as Board of DirectorParkerVision, Inc. announced that it has named Sanford (Sandy) Litvack to its Board of Directors, expanding the Board to five members, four of whom are independent. Mr. Litvack is a partner with Chaffetz Lindsey LLP and has a broad corporate litigation background, handling a wide array of complex matters, including patent and other intellectual property issues. Litvack served as Assistant Attorney General in charge of the Antitrust Division of the Department of Justice and was selected by President George W. Bush to serve as a member of the Antitrust Modernization Commission. In addition to his courtroom experience, Mr. Litvack spent a decade at the Walt Disney Company holding various roles from general counsel to chief of corporate operations and vice chairman of the board of directors. He is also a former director of Hewlett Packard. Mr. Litvack currently serves on the board of directors for L Catterton Asia Acquisition Corp., a special purpose acquisition company.
공시 • Aug 18ParkerVision, Inc. announced that it has received $1.6675 million in fundingOn August 17, 2022, ParkerVision, Inc. closed the transaction. The transaction included participation from 13 investors.
공시 • Aug 03ParkerVision, Inc., Annual General Meeting, Sep 16, 2022ParkerVision, Inc., Annual General Meeting, Sep 16, 2022, at 10:00 US Eastern Standard Time. Agenda: To elect two Class III members of the Board to hold office until the third ensuing annual meeting and until his respective successor is duly elected and qualified; to approve an amendment to the amended and restated articles of incorporation of the company, as amended, to increase the number of authorized shares of common stock from 150,000,000 shares to 175,000,000 shares; to ratify the appointment of MSL, P.A. as the company's independent registered public accounting firm for the year ending December 31, 2022; and to transact such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof.
공시 • Jul 02ParkerVision, Inc. announced that it has received $0.35 million in funding from Forge Trust Company, and other investorsParkerVision, Inc. announced that it has entered into a purchase agreement for a private placement of 8% unsecured convertible promissory notes for gross proceeds of $350,000on June 30, 2022. The transaction included participation from Forge Trust Company for $200,000, The Trustee of the Judson Dean LaCapra Revocable Trust for $25,000, individual investors John F. Levy for $100,000, Wilhem Boulay for $25,000. The notes bear interest at a fixed rate of 8% per annum and is payable quarterly either in cash, shares of common stock, or a combination thereof at the company's option, subject to certain equity conditions, on the 15th of April, July, October, and January of each year during the five year term of the notes, expiring June 30, 2027. The notes are convertible at any time and from time to time by the Holders into shares of common stock at a fixed conversion price of $0.13 per share. The company issued securities in reliance on the exemption afforded by Section 4(a)(2) of the Securities Act of 1933 and Rule 506(b) of Regulation D promulgated thereunder.
공시 • Jun 03ParkerVision, Inc. announced that it has received $0.76 million in funding from Alpine Partners (Bvi), L.P., Thomas Staz Revocable TrustParkerVision, Inc. announced that it has entered into a note and warrant purchase agreement for a private placement of 8% unsecured convertible promissory notes for gross proceeds of $760,000 on June 2, 2022. The transaction included participation from Thomas Staz Revocable Trust for $65,000, Alpine Partners (BVI) LP for $500,000, individual investors, Harold Wrobel for $130,000 and Ronald T. Bevans, Jr. for $65,000. The notes bear interest at a fixed rate of 8% per annum and is payable quarterly either in cash, shares of common stock, or a combination thereof at the company's option, subject to certain equity conditions, on the 15th of April, July, October, and January of each year during the five year term of the notes, expiring June 2, 2027. The notes are convertible at any time and from time to time by the Holders into shares of common stock at a fixed conversion price of $0.13 per share. The company issued securities in reliance on the exemption afforded by Section 4(a)(2) of the Securities Act of 1933 and Rule 506(b) of Regulation D promulgated thereunder.
공시 • Mar 29ParkerVision, Inc. Announces that Orlando Court Grants Qualcomm Motion for Summary JudgmentParkerVision, Inc. announced that on March 22, 2022, the U.S. District Court in the Middle District of Florida ruled in Qualcomm’s favor on a motion styled as Qualcomm’s motion for “non-infringement and invalidity” (Dkt. 494) in ParkerVision v. Qualcomm (Case no. 6:14-cv-00687). The court’s order, which is sealed “for attorney’s eyes only,” determines that Qualcomm does not infringe the asserted claims of the remaining three patents-in-suit. It makes no findings as to the invalidity of any of the asserted claims of the remaining three patents-in-suit. This is a final order, meaning the next step is an appeal. ParkerVision intends to appeal this ruling, along with this same court’s March 9, 2022 ruling excluding opinions of the Company’s experts regarding infringement and validity issues.
공시 • Mar 31ParkerVision, Inc. announced that it has received $3.6 million in fundingParkerVision, Inc. (OTCPK:PRKR) announced a private placement of units at an issue price of $1.29 per unit for gross priceeds of $3,600,000 on March 29, 2021. Each unit consists of one common share and half warrant. Each warrant is exercisable into shares at an exercise p[rice of $1.75 per share for a period of five years.
공시 • Oct 05Parkervision Inc. to Report Q4, 2009 Results on 03/15/2010Parkervision Inc. announced that they will report Q4, 2009 results on 03/15/2010
공시 • Aug 22+ 1 more updateParkerVision, Inc. announced that it has received $0.352701 million in funding from Gem Investment Advisors, LLCOn August 21, 2020, ParkerVision, Inc. closed the transaction. The company received $352,700 pursuant to regulation D.
공시 • Aug 07+ 1 more updateParkerVision, Inc. announced that it has received $0.1745 million in fundingOn August 6, 2020, ParkerVision, Inc. (OTCPK:PRKR) closed the transaction. The transaction included participation from 3 investors.
공시 • Jul 07ParkerVision, Inc. announced that it has received $0.215201 million in fundingParkerVision, Inc. (OTCPK:PRKR) announced that it has entered into securities purchase agreements to issue 614,859 shares at a price of $0.35 per share for gross proceeds of $215,201 on June 29, 2020. The purchase agreements also provide the investors with a contingent payment right whereby the company will pay each investor an allocated portion of the company’s net proceeds from its patent claims, after taking into account fees and expenses payable to law firms representing the company and amounts payable to the company’s litigation financer. The transaction will include participation from individual investors including Dennis Mehiel for 285,715 shares amounting to $100,000, Aileen Gregoire for 100,000 shares amounting to $35,000, Wenyu Luo for 85,715 amounting to $30,000, John Birdsall & Margaret Mintz for 72,000 amounting to $25,200, Manal Eldumiati for 71,429 amounting to $25,000. The shares will be offered and sold on a private placement basis under Section 4(a)(2) of the Securities Act of 1933 and Rule 506. The company received funding from 7 investors pursuant to Regulation D.